시장보고서

상품코드

1792289

유전자 발현 분석(GEA) 시장 보고서 : 제품 및 서비스별, 기술별, 능력별, 최종 사용자별, 지역별(2025-2033년)

Gene Expression Analysis Market Report by Products & Services, Technology (Polymerase Chain Reaction, Next Generation Sequencing, DNA Microarray, Sanger Sequencing, and Others), Capacity, End-User, and Region 2025-2033

발행일: 2025년 08월 | 리서치사:

IMARC | 페이지 정보: 영문 136 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 유전자 발현 분석 시장 규모는 2024년 56억 달러에 달했습니다. IMARC Group은 시장이 2033년까지 117억 달러에 이를 전망이며, 2025-2033년 8.21%의 성장률(CAGR)로 성장할 것으로 예측했습니다.

유전자 발현 분석(GEA)은 생물학적 시스템의 거동을 조사하기 위해 유전자에서 데이터를 추출하는 방법입니다. 유전자의 전사, 번역, 단백질의 번역 후 변형, RNA 스플라이싱 등 다양한 공정이 포함됩니다. 이 분석에서 얻은 데이터는 단백질, 리보 핵산(RNA) 및 다양한 미생물학적 제품 생산에 활용됩니다. 게다가 신약의 개발 및 기존의 진단법 개량에도 활용되고 있습니다. GEA는 현재 약리 유전체학, 바이오마킹, 독물학 및 진단학에 광범위하게 응용되고 있으며, 많은 의학적 질환의 원인 메커니즘을 설명하는데 필수적인 것으로 널리 간주되고 있습니다.

맞춤형 의료에 대한 수요가 증가함에 따라 표적 분자 치료제의 채용이 증가하고 있다는 것도 시장 성장을 가속하는 주요 요인 중 하나입니다. GEA는 분자 생물학적 연구에서 강력한 도구임이 입증되었으며 유전자의 기능을 이해하고 질병을 진단하며 의약품 개발을 촉진하는 데 사용됩니다. 또한 암, 결핵, 심혈관 질환, 유전성 질환 등 만성질환의 유병률 증가가 시장 성장을 크게 뒷받침하고 있습니다. 또한, 이러한 질병을 치료하기 위한 맞춤형 의약품의 개발은 개별 환자의 요구에 따라 진단 및 치료법을 변경할 수 있게 되었습니다. 또한 차세대 시퀀싱(NGS) 등장, 유전체 데이터베이스 개발, GEA 성공률 향상, 유전자 치료 연구개발(R&D)에 대한 주력 강화 등 다양한 기술적 진보가 시장 성장을 더욱 촉진할 것으로 예측됩니다.

이 보고서에서 다루는 주요 질문

세계의 유전자 발현 분석 시장 규모는?
세계 유전자 발현 분석 시장의 2025-2033년 예상 성장률은?
세계의 유전자 발현 분석 시장을 견인하는 주요인은?
세계의 유전자 발현 분석 시장에서 COVID-19의 영향은?
제품 및 서비스별 시장 내역은?
기술별 시장 내역은?
능력별 시장 내역은?
최종 사용자별 시장 내역은?
세계 유전자 발현 분석 시장의 주요 지역은?
세계의 유전자 발현 분석 시장에서 주요 기업은?

북미
- 미국
- 캐나다
유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
- 인도네시아
- 기타
라틴아메리카
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 칠레
- 페루
- 기타
중동 및 아프리카
- 튀르키예
- 사우디아라비아
- 이란
- 아랍에미리트(UAE)
- 기타

제11장 SWOT 분석

개요
강점
약점
기회
위협

제12장 밸류체인 분석

개요
인바운드 물류
오퍼레이션
아웃바운드 물류
마케팅과 판매
서비스

제13장 Porter's Five Forces 분석

개요
구매자의 협상력
공급기업의 협상력
경쟁도
신규 참가업체의 위협
대체품의 위협

제14장 가격 지표

제15장 경쟁 구도

시장 구조
주요 기업
주요 기업 프로파일
- Agilent Technologies, Inc.
- BGI Genomics Co., Ltd.
- Bio-Rad Laboratories, Inc.
- Eurofins GSC Lux SARL
- F. Hoffmann-La Roche Ltd
- GE Healthcare
- Illumina, Inc.
- Oxford Gene Technology IP Limited
- Pacific Biosciences of California Inc.
- PerkinElmer Inc.
- QIAGEN GmbH
- Thermo Fisher Scientific Inc.

AJY

The global gene expression analysis market size reached USD 5.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 11.7 Billion by 2033, exhibiting a growth rate (CAGR) of 8.21% during 2025-2033.

Gene expression analysis (GEA) is the method of extracting data from a gene to investigate the behaviour of biological systems. It involves different processes such as gene transcription, translation, post-translational modification of protein and RNA splicing. The data obtained from this analysis is used for the production of proteins, Ribonucleic Acid (RNA) and various microbiological products. They are further utilized for the development of new drugs and improving the existing diagnostic methods. GEA is now widely considered to be essential in explaining the mechanisms that cause numerous medical ailments, owing to which it finds extensive applications in pharmacogenomics, biomarking, toxicology and diagnostics.

The increasing adoption of targeted molecular therapeutics, along with the growing demand for personalized medicines, is among the key factors driving the growth of the market. GEA has proven to be a powerful tool in molecular biology studies, which are used to understand the functioning of genes, diagnose ailments and facilitate drug development. Furthermore, the growing prevalence of chronic diseases, such as cancer, tuberculosis, and cardiovascular and genetic disorders is providing a significant boost to the market growth. Additionally, the development of personalized medicines to cure these ailments has enabled the modifications of diagnostic and treatment methods according to the individual patient requirement. Moreover, various technological advancements, such as the advent of Next Generation Sequencing (NGS), along with the development of genomic databases, higher success rates of GEA and enhanced focus on research and development (R&D) in gene therapy, are further projected to drive the market growth.

Key Market Segmentation:

Breakup by Products & Services:

Consumables
Instruments
Services

Breakup by Technology:

Polymerase Chain Reaction (PCR)
Next Generation Sequencing (NGS)
DNA Microarray
Sanger Sequencing
Others

Breakup by Capacity:

Low-to Mid-Plex Gene Expression Analysis
High-Plex Gene Expression Analysis

Breakup by End-User:

Pharmaceutical and Biotech Companies
Academic Institutes and Research Centers
Others

Breakup by Region:

North America
- United States
- Canada
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Chile
- Peru
- Others
Middle East and Africa
- Turkey
- Saudi Arabia
- Iran
- United Arab Emirates
- Others

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Agilent Technologies, Inc., BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., Eurofins GSC Lux SARL, F. Hoffmann-La Roche Ltd, GE Healthcare, Illumina, Inc., Oxford Gene Technology IP Limited, Pacific Biosciences of California Inc., PerkinElmer Inc., QIAGEN GmbH, Thermo Fisher Scientific Inc. etc.

Key Questions Answered in This Report

1.How big is the global gene expression analysis market?
2.What is the expected growth rate of the global gene expression analysis market during 2025-2033?
3.What are the key factors driving the global gene expression analysis market?
4.What has been the impact of COVID-19 on the global gene expression analysis market?
5.What is the breakup of the global gene expression analysis market based on the product & services?
6.What is the breakup of the global gene expression analysis market based on the technology?
7.What is the breakup of the global gene expression analysis market based on the capacity?
8.What is the breakup of the global gene expression analysis market based on the end-user?
9.What are the key regions in the global gene expression analysis market?
10.Who are the key players/companies in the global gene expression analysis market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Gene Expression Analysis Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact Of COVID-19
5.4 Market Forecast

6 Market Breakup by Products & Services

6.1 Consumables
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Instruments
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Services
- 6.3.1 Market Trends
- 6.3.2 Market Forecast

7 Market Breakup by Technology

7.1 Polymerase Chain Reaction (PCR)
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Next Generation Sequencing (NGS)
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 DNA Microarray
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Sanger Sequencing
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast

8 Market Breakup by Capacity

8.1 Low-to Mid-Plex Gene Expression Analysis
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 High-Plex Gene Expression Analysis
- 8.2.1 Market Trends
- 8.2.2 Market Forecast

9 Market Breakup by End-User

9.1 Pharmaceutical and Biotech Companies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Academic Institutes and Research Centers
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Europe
- 10.2.1 Germany
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 France
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 United Kingdom
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 Italy
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Spain
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Russia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Asia-Pacific
- 10.3.1 China
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 Japan
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 India
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 South Korea
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Australia
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Indonesia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Argentina
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
- 10.4.4 Colombia
  - 10.4.4.1 Market Trends
  - 10.4.4.2 Market Forecast
- 10.4.5 Chile
  - 10.4.5.1 Market Trends
  - 10.4.5.2 Market Forecast
- 10.4.6 Peru
  - 10.4.6.1 Market Trends
  - 10.4.6.2 Market Forecast
- 10.4.7 Others
  - 10.4.7.1 Market Trends
  - 10.4.7.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Turkey
  - 10.5.1.1 Market Trends
  - 10.5.1.2 Market Forecast
- 10.5.2 Saudi Arabia
  - 10.5.2.1 Market Trends
  - 10.5.2.2 Market Forecast
- 10.5.3 Iran
  - 10.5.3.1 Market Trends
  - 10.5.3.2 Market Forecast
- 10.5.4 United Arab Emirates
  - 10.5.4.1 Market Trends
  - 10.5.4.2 Market Forecast
- 10.5.5 Others
  - 10.5.5.1 Market Trends
  - 10.5.5.2 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

12.1 Overview
12.2 Inbound Logistics
12.3 Operations
12.4 Outbound Logistics
12.5 Marketing and Sales
12.6 Service

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Indicators

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 Agilent Technologies, Inc.
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 Financials
  - 15.3.1.4 SWOT Analysis
- 15.3.2 BGI Genomics Co., Ltd.
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
- 15.3.3 Bio-Rad Laboratories, Inc.
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
  - 15.3.3.3 Financials
  - 15.3.3.4 SWOT Analysis
- 15.3.4 Eurofins GSC Lux SARL
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
- 15.3.5 F. Hoffmann-La Roche Ltd
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 Financials
- 15.3.6 GE Healthcare
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
- 15.3.7 Illumina, Inc.
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
  - 15.3.7.4 SWOT Analysis
- 15.3.8 Oxford Gene Technology IP Limited
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
  - 15.3.8.3 Financials
- 15.3.9 Pacific Biosciences of California Inc.
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
- 15.3.10 PerkinElmer Inc.
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
  - 15.3.10.3 Financials
  - 15.3.10.4 SWOT Analysis
- 15.3.11 QIAGEN GmbH
  - 15.3.11.1 Company Overview
  - 15.3.11.2 Product Portfolio
  - 15.3.11.3 Financials
- 15.3.12 Thermo Fisher Scientific Inc.
  - 15.3.12.1 Company Overview
  - 15.3.12.2 Product Portfolio
  - 15.3.12.3 Financials
  - 15.3.12.4 SWOT Analysis